TC
IMDZ

TFS Capital’s Immune Design Corp. IMDZ Stock Holding History

TFS Capital’s Portfolio IMDZ Stock Details IMDZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-102,685
Closed -$838K – 1229
2016
Q2 		$838K Buy
102,685
+49,867
+94% +$622K 0.15% 218
2016
Q1 		$687K Buy
+52,818
New +$610K 0.1% 362
2015
Q2 		– Sell
-23,977
Closed -$506K – 1294
2015
Q1 		$506K Buy
+23,977
New +$626K 0.05% 549

Other funds holding IMDZ

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

TFS Capital's IMDZ Position: Q3 2016 in Review

TFS Capital sold out of Immune Design Corp. (IMDZ) in Q3 2016, closing a stake of 102,685 shares — an estimated $838K sold.

TFS Capital first reported a position in IMDZ in Q1 2015 and held it in 3 quarters. The position peaked at $838K in Q2 2016. 59 funds tracked by Wall St. Rank hold IMDZ as of Q3 2016.

  • TFS Capital reported no remaining Immune Design Corp. position as of Q3 2016 after selling out during the quarter.
  • TFS Capital sold 102,685 Immune Design Corp. shares in Q3 2016, an estimated $838K.
  • TFS Capital first reported a position in Immune Design Corp. in Q1 2015 and held it in 3 quarters.
  • TFS Capital's Immune Design Corp. position peaked at $838K in Q2 2016.
  • 59 funds tracked by Wall St. Rank held Immune Design Corp. as of Q3 2016.

Based on TFS Capital's 13F filing for Q3 2016, filed 10 Nov 2016.